Table 3.

Feasibility outcome: compliance in TXA trial

	All (N = 100)	TXA (N = 49)	Placebo (N = 51)
Patients who received both doses of study drug, n (%; 95% CI)	89 (89.0; 81.2–94.4)	45 (91.8; 80.4–97.7)	44 (86.3; 73.7–94.3)
Patients who received only one dose of study drug, n (%; 95% CI)	2 (2.0; 0.2–7.0)	1 (2.0; <  0.1–10.8)	1 (2.0; <  0.1–10.4)
Patients who received no dose of study drug, n (%; 95% CI)	9 (9.0; 4.2–16.4)	3 (6.1; 1.3–16.9)	6 (11.8; 4.4–23.9)

TXA tranexamic acid, CI confidence interval.